Please login to the form below

Not currently logged in

Abbott's paediatric HIV drug wins FDA approval

US-based pharmaceutical company Abbott wins FDA approval for its lower-strength protease-inhibitor Kaletra, which will be available in the US from November 2007

US-based pharmaceutical company Abbott has won FDA approval for its lower-strength protease-inhibitor Kaletra (lopinavir/ritonavir), which will be available in the US from November 2007.

The new lower-strength tablets are smaller in size than original Kaletra tablets and contain the same proven active ingredients as Abbott's Kaletra oral solution. The lower-strength Kaletra tablet is approved for children weighing 15 kg or more who are able to swallow the intact tablet.

Scott Brun, divisional vice-president of infectious diseases and renal development at Abbott's global pharmaceutical R&D arm, said: "HIV/AIDS continues to have a devastating impact globally, especially among the more than two million children living with the disease throughout the world. Abbott developed a lower-strength tablet formulation of Kaletra to give doctors an innovative treatment option to help curb the impact of HIV infection in children."

30th September 2008


Featured jobs

Subscribe to our email news alerts


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?